Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 23, 2008
JNCI Journal of the National Cancer Institute 2008 100(19):1347-1349; doi:10.1093/jnci/djn357
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/19/1347    most recent
djn357v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sinha, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sinha, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

COSTLY CARE

Expensive Cancer Drugs With Modest Benefit Ignite Debate Over Solutions

Gunjan Sinha

The first 150 words of the full text of this article appear below.

Like many oncologists, Don Dizon, M.D., doesn't like to candy-coat bad news. "I try to be realistic about what we can accomplish with treatment," said Dizon, who specializes in treating gynecological cancers at Women and Infants Hospital of Rhode Island.

But it's in what he tells his patients afterward that Dizon may stray from the norm. Dizon also discusses with his patients the cost of drugs and the fact that their particular insurance may not cover them. Patients then meet with a hospital-appointed nurse manager, who not only explains chemotherapy to them but also helps them navigate the morass of health insurance coverage in the U.S. The nurse manager is responsible for figuring out whether a prescribed course of therapy will be covered by a patient's insurance. And if it isn't, that patient is sent to a hospital-appointed financial counselor who then explains that if insurance won't pay, the patient . . . [Full Text of this Article]

Costs Drive Change

Making Health Care Cost-effective

Expensive Drugs, Modest Benefit

Change Unlikely


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. Mileshkin, P. E. Schofield, M. Jefford, E. Agalianos, M. Levine, A. Herschtal, J. Savulescu, J. A. Thomson, and J. R. Zalcberg
To Tell or Not to Tell: The Community Wants to Know About Expensive Anticancer Drugs As a Potential Treatment Option
J. Clin. Oncol., December 1, 2009; 27(34): 5830 - 5837.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
N. Mittmann, H.-J. Au, D. Tu, C. J. O'Callaghan, P. K. Isogai, C. S. Karapetis, J. R. Zalcberg, W. K. Evans, M. J. Moore, J. Siddiqui, et al.
Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial
J Natl Cancer Inst, September 2, 2009; 101(17): 1182 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
R. K. Jain, D. G. Duda, and A. G. Sorensen
Emerging Paradigms and Potential Biomarkers of Response and Resistance in Antiangiogenic Therapy of Cancer
ASCO Educational Book, January 1, 2009; 2009(1): 716 - 721.
[Abstract] [Full Text] [PDF]